ABOUT US
Introduction
Chairman's Statement
Contact Us
R&D
R&D Platforms
R&D Capability
R&D Center
Scientific Activities
PRODUCTS
bFGF Series
other ophthalmic products
other surgical products
NEWS
company news
investee news
media focus
INVESTOR RELATIONS
Announcements & Shareholder Info
Corporate Info
Financial & ESG Reports
Contact Us
CAREERS
Talent Concept
Job Opportunities
简
繁
EN
ABOUT US
Introduction
Chairman's Statement
Contact Us
R&D
R&D Platforms
R&D Capability
R&D Center
Scientific Activities
PRODUCTS
bFGF Series
other ophthalmic products
other surgical products
NEWS
company news
investee news
media focus
INVESTOR RELATIONS
Announcements & Shareholder Info
Corporate Info
Financial & ESG Reports
Contact Us
CAREERS
Talent Concept
Job Opportunities
简
繁
EN
简
繁
EN
SCIENTIFIC ACTIVITIES
bFGF alleviated dry eye disease by modulating inflammatory response and promoting healing process both in vitro and in vivo.
2021.05.06
Time
Last 7 days
Last 30 days
The last six months
Date
Title
2021-05-06
bFGF alleviated dry eye disease by modulating inflammatory response and promoting healing process both in vitro and in vivo.
ARVO 2021 Annual Meeting
2020-12-24
Tackling solid tumour therapy with small-format drug conjugates.
Antibody Therapeutics, 2020, Vol. 3, No. 4
2019-07-31
Safety and Efficacy of First-in-Class mtROS scavenger SkQ1 for the Treatment of Dry Eye Disease: A Phase 3 Clinical Trial
. Investigative Ophthalmology & Visual Science July 2019, Vol.60, 6750. doi:
<
1
>
